ClearPoint Neuro
ClearPoint Neuro's revenue rose 17.8% to $37 million in fiscal 2025. Its operating margin was −65.4%, down from −62.9% a year earlier. Free cash flow was −$24 million. The diluted share count rose 4.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What ClearPoint Neuro does
ClearPoint Neuro makes systems for minimally invasive brain surgery. Its main product, the ClearPoint system, combines hardware, disposable parts and software to guide surgeons as they place deep brain stimulation electrodes, biopsy needles and laser catheters, and as they infuse drugs into the brain. It was first designed for use inside an MRI scanner, and the company has since added versions for the operating room.
It also sells the ClearPoint Prism laser ablation system, which another company makes for it. In 2025 it acquired IRRAS Holdings, which added the IRRA flow system. That device handles irrigation, drainage and pressure monitoring inside the skull for neurocritical care.
The company has a second part to its business: partnerships with drug and biotech companies, academic groups and research organizations that use its products to inject gene and cell therapies directly into the brain. It also provides preclinical development and consulting services, and it says a growing and significant part of its revenue has come from these services since 2021.
Its biggest risks, as it describes them
- It may not realize the expected benefits of its acquisition of IRRAS.
- Its ClearPoint and IRRA flow systems may not win broad market adoption.
- Inadequate coverage and payment from insurers for procedures that use its products could hurt adoption.
- A few customers make up a large part of its business.
Income statement
ClearPoint Neuro lost money in fiscal 2025: a net loss of $26 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 54 | 38 | 23 | 20 | 46 |
| Debt incl. finance leases | 10 | 10 | 10 | 0 | 49 |
| Net debt (negative means net cash) | −44 | −28 | −13 | −20 | 3 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.2x | 0.3x | 0.5x | 0.0x | 1.8x |
| Interest coverage | −13.8x | −201.6x | −30.2x | −38.1x | −10.1x |
| Current ratio | 13.0x | 7.5x | 4.9x | 3.2x | 5.9x |
| Quick ratio | 12.0x | 6.2x | 3.8x | 2.6x | 5.1x |
Cash flow
Projections
Project ClearPoint Neuro's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought ClearPoint Neuro shares on the open market, and 4 insiders sold $2.5 million, $2.2 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 29, 2026 | Joseph BurnettCEO and President, Director | Sold plan | 20,000 | $19.38 | $387,600 | Form 4 |
| Jun 17, 2026 | Joseph BurnettCEO and President, Director | Sold plan | 61,843 | $17.79 | $1.1 million | Form 4 |
| Jun 1, 2026 | Timothy T. RichardsDirector | Sold | 5,415 | $12.17 | $65,901 | Form 4 |
| May 21, 2026 | Matthew B. KleinDirector | Sold | 16,000 | $11.59 | $185,440 | Form 4 |
| May 20, 2026 | Lynnette C FallonDirector | Sold plan | 5,091 | $11.14 | $56,714 | Form 4 |
| Feb 25, 2026 | Joseph BurnettCEO and President, Director | Sold plan | 19,951 | $15.17 | $302,657 | Form 4 |
| Jan 26, 2026 | Joseph BurnettCEO and President, Director | Sold plan | 2,943 | $15.57 | $45,823 | Form 4 |
| Jan 9, 2026 | Joseph BurnettCEO and President, Director | Sold plan | 20,000 | $16.12 | $322,400 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 9 | 4 of 9 | 4 of 9 |
| Rule of 40 | −43.7% | 1.6% | −48.4% |
| Altman Z'' | −11.26 | −13.52 | −4.93 |
| Accruals ratio | −17.1% | −24.4% | −2.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 2 of 9 | 4 of 9 | 4 of 9 |
Compare
Put ClearPoint Neuro side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| ClearPoint Neuro | FY25 | 17.8% | −65.4% | −66.1% | −104.7% | — | 4 | |
| CytoSorbents | FY25 | 4.1% | −39.8% | −33.8% | — | — | — | Compare |
| Utah Medical Products | FY25 | −5.8% | 29.6% | 37.2% | 26.8% | −6.0x | 6 | Compare |
| Senseonics | FY25 | 56.9% | −193.8% | −170.9% | — | — | 4 | Compare |
| Pulsenmore | FY25 | 314.3% | — | −82.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 6 | 7 | 7 | 11 | 13 | 16 | 21 | 24 | 31 | 37 |
| Revenue growth | 25.1% | 28.4% | −0.4% | 52.5% | 14.4% | 27.1% | 26.1% | 16.6% | 31.0% | 17.8% |
| Gross profit | 3 | 4 | 5 | 7 | 9 | 11 | 14 | 14 | 19 | 23 |
| Research and development | 3 | 3 | 2 | 3 | 5 | 9 | 11 | 12 | 12 | 14 |
| Operating income | −8 | −6 | −5 | −5 | −6 | −13 | −16 | −22 | −20 | −24 |
| Net income | −8 | −7 | −6 | −6 | −7 | −14 | −16 | −22 | −19 | −26 |
| Diluted EPS (US$) | −2.93 | −0.93 | −0.56 | −0.42 | −0.43 | −0.69 | −0.68 | −0.90 | −0.70 | −0.90 |
| Diluted shares (millions) | 3 | 8 | 11 | 13 | 16 | 21 | 24 | 25 | 27 | 28 |
| Cash flow | ||||||||||
| Cash from operations | −6 | −6 | −5 | −3 | −8 | −13 | −16 | −14 | −9 | −24 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Free cash flow | −6 | −6 | −5 | −3 | −8 | −13 | −16 | −14 | −9 | −24 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 6 | 7 | 8 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 3 | 9 | 3 | 6 | 20 | 54 | 38 | 23 | 20 | 46 |
| Debt incl. finance leases | 4 | 5 | 4 | 2 | 21 | 10 | 10 | 10 | 0 | 49 |
| Total assets | 7 | 14 | 8 | 12 | 30 | 66 | 56 | 43 | 39 | 98 |
| Total liabilities | 8 | 8 | 6 | 7 | 27 | 17 | 19 | 22 | 14 | 70 |
| Shareholders' equity | −1 | 6 | 2 | 5 | 2 | 49 | 37 | 21 | 25 | 28 |
| Margins and ratios | ||||||||||
| Gross margin | 54.0% | 60.7% | 66.9% | 64.9% | 71.1% | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Operating margin | −130.2% | −85.9% | −71.4% | −41.0% | −48.5% | −82.0% | −79.5% | −93.7% | −62.9% | −65.4% |
| Net margin | −140.4% | −97.1% | −83.8% | −49.4% | −52.9% | −88.4% | −80.0% | −92.2% | −60.2% | −69.1% |
| Free cash flow margin | −103.0% | −81.6% | −63.8% | −25.5% | −61.2% | −78.9% | −79.9% | −60.3% | −29.4% | −66.1% |
| Rule of 40 (growth + FCF margin) | −77.8% | −53.2% | −64.2% | 27.1% | −46.8% | −51.9% | −53.8% | −43.7% | 1.6% | −48.4% |
| Return on capital | — | — | −247.8% | −254.5% | −217.4% | — | −186.9% | −205.3% | −235.0% | −104.7% |
| Return on equity | — | −282.6% | −168.0% | −181.8% | −194.8% | −56.3% | −38.4% | −76.1% | −81.2% | −95.6% |
| Return on assets | −93.1% | −67.3% | −56.7% | −56.0% | −32.7% | −30.3% | −27.1% | −45.0% | −46.2% | −37.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |